Gelomyrtol Forte 2x20 Capsules

Product Information

Trys pagrindinės medžiagos daugiausiai pašalinamos su šlapimu metabolitų pavidalu. Dalis iškvėpiama. Tesche and colleagues conducted a double-blind randomized trial comparing a herbal preparation containing five components, possibly resembling Sinupret, with cineole [ 43]. Of note, this study did not clearly state using Sinupret when refering to the composition of the preparation. Furthermore, no placebo group was included in the study. The study recruited a total of 150 patients across three centres, with 75 patients randomized to each treatment group. Two capsules containing 200 mg of cineole were given three times daily and one tablet of the 5-component herbal preparation was given three times daily. Each treatment was given for 7 days and a spray of xylometazoline was given as concomitant medication to alleviate nasal obstruction. Plant-based congestion aid GeloMyrtol® forte is suitable for use in children as young as 6 years old, with minimal bothersome side effects. GeloMyrtol® forte is also available in smaller capsule form as Myrtol®. These smaller oval capsules are easy to swallow. Bronchitis become

A burning throat, difficulty swallowing, and eating and drinking become torture – sore throats can take different forms and have different causes, but one thing is certain: they can make everyday life more difficult. There are no concerns about long-term use. GeloMyrtol ® forte is also used successfully for chronic bronchitis and sinusitis. In decades of therapeutic use in clinics and practices, it has proven to be very well tolerated and effective. Very many patients with chronic sinusitis or chronic bronchitis have long-term use of GeloMyrtol ® forte has had very good experiences over the years. In patients with chronic bronchitis, a large clinical study lasting 6 months showed that the administration of GeloMyrtol ® forte over the winter months significantly reduced the intensity and frequency of acute infections. * Visada vartokite šį vaistą tiksliai kaip nurodė gydytojas arba vaistininkas. Jeigu abejojate, kreipkitės į gydytoją arba vaistininką.No responsibility is taken for the correctness of this information. The listed offers do not constitute legally binding advertising claims of the merchants. The herbal expectorant GeloMyrtol ® forte is suitable and well tolerated for children from 6 years of age. GeloMyrtol ® forte is also available as a smaller capsule: Myrtol ®. The smaller, oval capsules are particularly easy to swallow. Minimizing the systemic activity of intranasal steroids is an important consideration to reduce the risk of hypothalamic pituitary adrenal (HPA) axis suppression. In a subsequent double-blind, randomized clinical trial, a lower dose of MFNS (200 μg twice daily, n = 318) was compared with the dose of MFNS used previously (400 μg twice daily, n = 324) or placebo ( n = 325), again in combination with antibiotics [ 47]. The decrease in TSS from baseline to Day 15 – the primary endpoint – was minimally greater with MFNS 200 μg (5.89, p = 0.014 versus placebo) and MFNS 400 μg (5.86, p = 0.017 versus placebo) than with placebo (5.22). The differences between the three groups persisted from baseline to Day 21. Likewise, individual symptom scores such as congestion, facial pain, rhinorrhea and post-nasal drip showed greater improvement with MFNS than with placebo. Most adverse events were mild or moderate in intensity, but included headache and epistaxis. The cosyntropin stimulation test indicated the absence of suppression of the HPA axis with both doses of MFNS. If there is significant heterogeneity in the included trials, then we will conduct subgroup analysis according to the region of the studies, age, stage of the subjects, types of treatments, and different outcomes. 2.5.2 Sensitivity analysis

The authors thank TopEdit ( www.topeditsci.com) for its linguistic assistance during the preparation of this manuscript. Author contributions Neubauer N, Marz RW. Placebo-controlled, randomized double-blind clinical trial with Sinupret(R) sugar coated tablets on the basis of a therapy with antibiotics and decongestant nasal drops in acute sinusitis. Phytomedicine. 1994;1:177–81. https://doi.org/10.1016/S0944-7113(11)80061-9.

Lacteol®

Zalmanovici Trestioreanu A, Yaphe J. Intranasal steroids for acute sinusitis. Cochrane Database Syst Rev. 2013:CD005149. https://doi.org/10.1002/14651858.CD005149.pub4. Passali D, Spinosi MC, Crisanti A, Bellussi LM. Mometasone furoate nasal spray: a systematic review. Multidiscip Respir Med. 2016;11:18. https://doi.org/10.1186/s40248-016-0054-3. Pohl-Boskamp introduced the first head lice treatment with a physical mode of action in Germany, which made them a pioneer on the German market. Many years of experience, clinically proven efficacy and expertise make NYDA® the number 1* head lice treatment brand in Germany today and the most frequently prescribed head lice remedy. Dėl veikliosios medžiagos tirpumo riebaluose, labai tikėtinas mažų koncentracijų patekimas į motinos pieną. Duomenų apie padidėjusį pavojų žindymo laikotarpiu vartojant Gelomyrtol/Gelomyrtol forte iki šiol gauta nebuvo. Kaip ir prieš vartojant kitokių vaistinių preparatų, žindymo laikotarpiu reikia pasitarti su gydytoju. Gyvūnų tyrimais patinų ir patelių vaisingumo sutrikimas nenustatytas. Tyrimų su žiurkėmis metu nustatyta, kad 1,8 cineolas prasiskverbia pro placentą. Tačiau mažesnėmis už toksines dozes, pre ir postnataliniam vystymuisi jos įtakos nedarė.

Gottschlich S, Roschmann K, Candler H. Phytomedicines in acute rhinosinusitis: a prospective, non-interventional parallel-group trial. Adv Ther. 2018;35:1023–34. https://doi.org/10.1007/s12325-018-0736-7. Išgrynintų eukaliptų,saldžiųjų apelsinų,mirtų,citrinų eterinių aliejų mišinio(66:32:1:1)distiliatas Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50:1–12. https://doi.org/10.4193/Rhino50E2.The high dose of EPs 7630 was defined as 60 drops three times daily [ 23]. The mean SSID in CIS from baseline to Day 3 and from baseline to Day 5 – the primary endpoint – was 16.0 ± 7.4 points with the high dose of EPs 7630 group and 8.3 ± 7.6 points with placebo ( p< 0.0001). As with the standard dose, patients in the EPs 7630 group reported greater improvement in ability to work and quality of life than patients in the placebo group. Adverse events were more frequent in the high-dose EPs 7630 group (15.4%) than in the placebo group (5.8%), the most frequent of which were mild epistaxis and mild epigastric discomfort. None of the adverse events reported were severe and no serious adverse events were reported. The overuse of antibiotics for unjustified indications such as the management of acute uncomplicated rhinosinusitis has contributed to the emergence of antibiotic-resistant strains of bacteria and prompted the need for alternative treatments. This review assesses the quality of evidence for the management of acute rhinosinusitis with herbal products, with the goal of positioning them among other treatments and identifying future research directions. The MEDLINE database was searched for randomized controlled trials with Sinupret®, Pelargonium sidoides extract, Cyclamen europaeum (CE), cineole, and GeloMyrtol®. Searches with N-acetylcysteine and mometasone furoate nasal spray (MFNS) were performed to compare the strength of evidence of herbal products to these conventional products, which are indicated for acute rhinosinusitis. Main body

GeloMyrtol ® forte is a good decision in every phase of the cold. Taking it at the first sign of a cold can avert the disease before the infection sets in. The self-cleaning mechanism of the airways is activated. Similar benefits of Sinupret (BNO 1016) were reported in patients with acute viral rhinosinusitis, in a robustly designed double-blind randomized controlled trial [ 14, 15]. In contrast to the trial conducted by Neubauer and März, patients did not receive treatments for acute rhinosinusitis other than the study drug, and there was a higher proportion of women than men in both treatment groups [ 14]. This trial randomized 386 patients ( n = 194 in the Sinupret group and n = 192 in the placebo group). Patients received two tablets of Sinupret 80 mg or placebo, three times daily for 15 days. In the intent-to-treat (ITT) population ( n = 190 in each group), the number of patients considered to be healed (investigator-assessed major symptom score [MSS] ≤ 1) was significantly higher in the Sinupret group than in the placebo group (48.4% vs. 35.8%; p = 0.0063) at the end of treatment. The number needed to treat (NNT) for patients to have MSS ≤ 1 at the end of treatment was eight in the ITT. This result was corroborated by patient-assessed MSS, the 20-item questionnaire sino-nasal outcome test (SNOT-20) German-adapted version (GAV), and ultrasonography imaging. The incidence of adverse events was similar between the two groups. The per-protocol (PP) analysis of the trial gave results concurrent with the ITT analysis [ 14, 15]. One of the possible limitations of the trial was the way in which rhinosinusitis symptoms were rated by investigators, based on patient description, instead of a direct assessment by the patient. Results of this large trial were pooled with those of a trial with a similar design to confirm the efficacy of Sinupret in acute rhinosinusitis in a large patient population ( n = 589) [ 13]. The pooled analysis confirmed previous results, with a greater improvement in MSS and quality of life outcomes in the Sinupret versus placebo group. Duomenų apie Gelomyrtol ir Gelomyrtol forte kapsulių poveikį žmonių vaisingumui nėra. Gydymo Gelomyrtol ir Gelomyrtol forte kapsulėmis poveikis žiurkių poravimuisi ir vaisingumui nebuvo nustatytas (žr. 5.3 skyrių).A range of herbal products have been evaluated for treating acute rhinosinusitis in randomized clinical trials. Sinupret is supported with the strongest evidence base, including adequately powered multicenter clinical trials, followed by EPs 7630, which is supported by smaller studies. Across the range of other herbal products, including CE nasal spray, GeloMyrtol, and cineole, only one randomized trial is available at best for each product. Furthermore, each trial identified in this review was conducted in a single country without power calculations and a small number of participants. Ideally, adequately powered international multicenter trials would be required to confirm or discredit findings and provide further credibility for these products. jei yra alergija eukalipto aliejui, saldžiųjų apelsinų aliejui, mirtos aliejui, citrinos aliejui arba cineolui (svarbiausiam eukalipto aliejaus komponentui) arba bet kuriai pagalbinei šio vaisto medžiagai (jos išvardytos 6 skyriuje); Laikyti ne aukštesnėje kaip 25 °C temperatūroje. Laikyti gamintojo pakuotėje, kad preparatas būtų apsaugotas nuo drėgmės. Lizogub et al. and Riley et al. tested two doses of Pelargonium sidoides extract in a two-part randomized double-blind clinical trial where the standard dose of EPs 7630P was compared with placebo [ 22] and a high dose of EPs 7630 was compared with placebo [ 23]. Patients were randomly assigned to the part of the trial examining standard dose versus placebo or the part of the trial examining high dose versus placebo [ 23]. Once allocated to a part of the trial, patients were then randomized to either treatment group. Patients included had either two major cold symptoms and one minor cold symptom, or one major cold symptom and three minor cold symptoms. The symptoms had to be present for 24 to 48 h. An ITT analysis was used. Gillissen A, Wittig T, Ehmen M, Krezdorn HG, de Mey C. A multi-centre, randomised, double-blind, placebo-controlled clinical trial on the efficacy and tolerability of GeloMyrtol(R) forte in acute bronchitis. Drug Res (Stuttg). 2013;63:19–27. https://doi.org/10.1055/s-0032-1331182.